A share price of Rigel Pharmaceuticals [RIGL] is currently trading at $35.19, down -2.57%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RIGL shares have gain 11.43% over the last week, with a monthly amount glided 23.91%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rigel Pharmaceuticals [NASDAQ: RIGL] stock has seen the most recent analyst activity on November 05, 2025, when Jefferies upgraded its rating to a Buy but kept the price target unchanged to $42 for it. On June 09, 2022, downgrade downgraded it’s rating to Neutral. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $1 on June 08, 2022. Cantor Fitzgerald downgraded its rating to a Neutral and reduced its price target to $1 on June 08, 2022. B. Riley Securities started tracking with a Neutral rating for this stock on March 23, 2022, and assigned it a price target of $4. In a note dated November 09, 2020, JP Morgan downgraded an Neutral rating on this stock.
Rigel Pharmaceuticals experienced fluctuations in its stock price throughout the past year between $14.63 and $43.72. Currently, Wall Street analysts expect the stock to reach $40 within the next 12 months. Rigel Pharmaceuticals [NASDAQ: RIGL] shares were valued at $35.19 at the most recent close of the market. An investor can expect a potential return of 13.67% based on the average RIGL price forecast.
Analyzing the RIGL fundamentals
Trailing Twelve Months sales for Rigel Pharmaceuticals [NASDAQ:RIGL] were 282.08M which represents 25.59% growth. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at 0.42%, Pretax Profit Margin comes in at 0.41%, and Net Profit Margin reading is 0.4%. To continue investigating profitability, this company’s Return on Assets is posted at 0.47, Equity is 2.05 and Total Capital is 0.8. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.52.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 34.58 points at the first support level, and at 33.98 for the second support level. However, for the 1st resistance point, the stock is sitting at 35.85, and for the 2nd resistance point, it is at 36.52.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Rigel Pharmaceuticals [NASDAQ:RIGL] is 2.28. Also, the Quick Ratio is 2.14, while the Cash Ratio stands at 0.51. Considering the valuation of this stock, the price to sales ratio is 2.26, the price to book ratio is 5.43 and price to earnings (TTM) ratio is 5.71.
Transactions by insiders
Recent insider trading involved Schorno Dean L, EVP & Chief Financial Officer, that happened on Feb 04 ’25 when 2036.0 shares were sold. EVP & Chief Financial Officer, Schorno Dean L completed a deal on Feb 05 ’25 to sell 1734.0 shares. Meanwhile, EVP, Chief Commercial Officer Santos David A sold 2125.0 shares on Feb 04 ’25.
